Status:
COMPLETED
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
Lead Sponsor:
Vanda Pharmaceuticals
Conditions:
Motion Sickness
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Randomized, double-blind, placebo-controlled investigating the efficacy of tradipitant in the treatment of motion sickness.
Eligibility Criteria
Inclusion
- Male or non-pregnant, non-lactating female patients aged 18 - 75 years (inclusive);
- Body Mass Index (BMI) of ≥18 and \<40 kg/m2;
- History or symptoms consistent with motion sickness
Exclusion
- Chronic nausea due to condition other than motion sickness;
- A positive test for drugs of abuse at the screening or evaluation visits;
- Clinically significant deviation from normal clinical laboratory results
Key Trial Info
Start Date :
December 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 27 2019
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT03772340
Start Date
December 20 2018
End Date
June 27 2019
Last Update
May 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vanda Investigational Site
Santa Monica, California, United States, 90404